Hemogenyx Pharmaceuticals PLC Broker's Research Note

TIDMHEMO

Hemogenyx Pharmaceuticals PLC

31 July 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Broker's Research Note

We are pleased to inform investors that the recently published research note by our corporate broker, SP Angel Corporate Finance LLP, is available to view on the Company's web site at https://hemogenyx.com/broker-coverage/ . The note updates SP Angel's original Initiation of Research note of August 2019.

Enquiries:

 
 Hemogenyx Pharmaceuticals plc           https://hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive   [e-mail] 
  Officer & Co-Founder 
 Peter Redmond, Director                 [e-mail] 
 
 SP Angel Corporate Finance LLP          Tel: [phone] 
                                          0470 
 Matthew Johnson, Vadim Alexandre, 
  Soltan Tagiev 
 
 Peterhouse Capital Limited              Tel: [phone] 
                                          0930 
 Lucy Williams, Duncan Vasey, Charles 
  Goodfellow 
 
 
 
 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a Belgian subsidiary, Hemogenyx-Cell SPRL, located in Liège.

Hemogenyx Pharmaceuticals is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The Company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx Pharmaceuticals' technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAKKFBDFBKDFOB

(END) Dow Jones Newswires

July 31, 2020 02:00 ET (06:00 GMT)